BNTC is the ticker symbol for Benitec Biopharma Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks BNTC with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is BNTC a good stock to buy?

BNTC is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/BNTC.

Where does 13F Pro source BNTC data?

All Benitec Biopharma Inc. fundamentals and ownership data come directly from SEC EDGAR. Benitec Biopharma Inc. files with the SEC under CIK 1808898. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Benitec Biopharma Inc.(BNTC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

Benitec Biopharma Inc. (BNTC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BNTC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $12.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q1 2026), Benitec Biopharma Inc. reports net income of $-11.9M, free cash flow of $-4.5M. Top institutional holders of BNTC by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, Jupiter Topco, FRANKLIN RESOURCES, based on the most recent SEC filings. BNTC trades on the Nasdaq exchange and files with the SEC under CIK 1808898. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Benitec Biopharma Inc. directly from SEC EDGAR.

Revenue

$0.00

Net Income

$-11.9M

Free Cash Flow

$-4.5M

BNTC key financials by period

Benitec Biopharma Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2023	10-K	$75.0K	$-19.6M	—
FY 2022	10-K	$73.0K	$-18.2M	—
FY 2021	10-K	$59.0K	$-13.9M	—
FY 2020	10-K	$102.0K	$-8.3M	—
FY 2019	10-K	$12.2M	$2.6M	21.2%

Institutions holding BNTC

Institutional investors reporting a position in Benitec Biopharma Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
SUVRETTA CAPITAL MANAGEMENT	11,548,351	$154.5M	2026-06-30
Jupiter Topco	2,478,547	$33.1M	2026-06-30
FRANKLIN RESOURCES	2,412,888	$32.3M	2026-06-30
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,120,672	$28.4M	2026-06-30
RA CAPITAL MANAGEMENT, L.P.	1,850,000	$24.8M	2026-06-30
Nantahala Capital Management	1,488,371	$19.9M	2026-06-30
BlackRock	1,407,138	$18.8M	2026-06-30
Simplify Asset Management	1,005,557	$13.5M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	954,533	$12.8M	2026-06-30
INFINITUM ASSET MANAGEMENT	923,006	$12.3M	2026-06-30

SEC EDGAR: CIK 1808898 →

Benitec Biopharma Inc.

BNTC

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $12.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.